Karyopharm plans to merge with Ayrmid, the company that tried buying bluebird
With few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeutics, maker of the multiple myeloma drug ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.